true

Advancing the world of health™

About BD
Segments
Ethics and Compliance

BD is one of the largest global medical technology companies in the world and is advancing the world of health^TMby improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare.

At BD, we are committed to a strong ethics and compliance culture. We do not tolerate actions or behaviors that are inconsistent with our values or violate the BD Code of Conduct or applicable laws and regulations. All BD associates are responsible fo reinforcing our ethics and compliance culture and sustaining our reputation as a company dedicated to quality and integrity. We encourage and expect everyone at BD to speak up by asking questions, raising concerns, seeking guidance, and reporting actual or suspected violations of laws, our Code of Conduct, our policies, or our high ethical standards. This requirement extends to all associates, vendors, and other third parties working on our behalf.

Learn More

Our Values

We do what is right

We thrive on innovation and demand quality

We are all accountable

We learn and improve every day

We help each other be great

2020 BD launched the first Human Papillomavirus (HPV) test with extended genotyping to detect more types of HPV, the dominant cause of cervical cancer.

2020 BD launched the first sample preparation and flow cytometry system to enable clinical laboratories to fully automate the sample-to-answer process.

2020 BD launched the BD Veritor™ Plus System for rapid detection of COVID-19

2021 BD launched the first atherectomy and thrombectomy device in the U.S. indicated to treat in-stent restenosis.

2021 BD launched the first at-home system in the U.S. indicated for malignant and non-malignant ascites drainage.

2021 BD launched the first ready-to-use aqueous povidone-iodine (PVP-I) surgical irrigation solution.

2021 BD launched the first assay for HPV screening from at-home, self-collected vaginal samples.

2021 BD launched the first smartphone-interpreted rapid at-home COVID-19 test.

2022 BD becomes the first company to combine flow cytometry with fluorescence imaging and image-based decisioning to sort individual cells based on visual details of the cell at exceptionally high speed (15,000 cells per second).

2022 BD celebrates their 125^th anniversary by ringing the closing bell at the New York Stock Exchange.

2010 BD Ultra-Fine™ Nano™ Pen Needle is launched.

2014 BD AutoShield Duo™ Safety Pen Needle with Duel Automatic Protective Shields is launched at retail.

2014 BD launched the first FDA-approved drug coated balloon for peripheral artery disease.

2015 BD became the first to integrate IV pumps with electronic health records.

2015 BD acquired CareFusion, a San Diego, California-based medical technology company specializing in two areas: reducing medication errors and prevention of health care-associated infections.

2017 The first clinical lab application of artificial intelligence and robotics to automatically report and release negative urine cultures is utilized.

2017 BD acquired C. R. Bard, a medical device company founded in 1907 in Covington, Georgia.

2019 BD launched the first CHG antiseptic skin preparation product with sterile solution in the U.S.

2019 BD launched the first venous stent to treat iliofemoral venous occlusive disease.

2000 BD launched the BD Nexiva™ Closed IV Catheter System.

2002 BD opened new distribution center in Redlands, California.

2003 BD launched the BD FACSAria™ Cell Sorter.

2004 BD introduced the first power-injectable PICC (Peripherally Inserted Central Catheter).

2007 BD participates in PEPFAR, the U.S. government's global effort to combat HIV and the largest global health program devoted to a single disease.

2007 BD AutoShield™ needle is launched.

2009 BD Vacutainer® RST™ Tube is approved by the FDA.

1990 Sales surpass $2,000,000,000 for the first time.

1991 BD launched the first auto-disable immunization device.

1991 Pen needle is introduced.

1991 BD opens a central distribution center in Temsee, Belgium to ship medical products across Europe, the middle east, and Africa.

1992 BD introduced the BD Vacutainer® Safety-Lok™ Blood Collection Set.

1993 BD launched the first simplified CD4 instrument for HIV.

1995 A joint venture was established in China to produce medical products for China.

1995 BD formed a subsidiary in India to manufacture insulin syringes and to market other medical and diagnostic products to the region.

1997 BD celebrated their 100th anniversary with a refresh to their brand identity.

1999 BD announced a 5-year partnership with UNICEF and the U.S. Fund for UNICEF to help eliminate maternal and neonatal tetanus worldwide.

1999 The world’s shortest, thinnest insulin pen needle is introduced.

1980 BD launched the first automated system for mycobacteria testing.

1981 BD launched the Bactec™ 460TB instrument – the first automated system for TB testing.

1981 A new plant is built in Plymouth, England to manufacture BD Vacutainer® system products and serve a growing European market.

1981 BD sales surpassed $1,000,000,000 for the first time.

1985 BD became the first to harness the highly specific bind properties of monoclonal antibodies.

1986 BD HQ is moved from Rutherford, NJ to Franklin Lakes, NJ.

1986 BD builds a leadership position in peripheral vascular access devices.

1987 BD opened a new manufacturing facility in Singapore.

1987 BD built a plant to manufacture diagnostic products in Fukushima, Japan.

1988 BD launched the first safety engineered syringe.

1989 BD launched the Pyxis MedStation™ 1000 System: the world’s first automated medication dispensing cabinet.

1971 BD launched the Baby Bird® ventilator, the first infant ventilator.

1971 BD launched the first automated blood culture system.

1972 BD launched the first florescence-activated cell sorter.

1973 BD opened a new research center in Research Triangle Park, North Carolina.

1975 BD opened its European HQ in Meylan, France.

1961 BD introduced the Plastipak™ Syringe.

1962 BD launched the first mass production of syringes and needles.

1962 BD became a public company.

1963 BD invited to join the New York Stock Exchange.

1968 BD introduced the first automated blood culture system for TB.

1952 BD launched the first sterile disposable medical device.

1952 BD acquired MAPAD, S.A. de C.V. based in Mexico City, to produce syringes, needles and clinical thermometers for the Mexican market.

1951 The formation of BD Canada, Ltd. marks the beginning of BD international expansion.

1954 Production of the first disposable syringes to be used in the Salk Polio vaccine trial takes place.

1955 BD enters the microbiology field leading to two fundamental innovations: The conversion of sterilized disposables and the emergence of diagnostic medicine.

1955 BD begins using AMI of France to manufacture steel tubes for hypodermic needles. Three years later, BD would acquire AMI and establish BD France S.A.

1956 BD enters the Brazilian syringe market and quickly becomes the largest provider in the country with two modern plants and HQ in Sao Paulo.

1940 BD launched the first sterilization technology for devices.

1942 BD launched the first penicillin injection kit.

1947 BD hired Joseph Kleiner, who brings his multi-fit syringe and his idea for the evacuated tube. (Patented in 1949)

1948 BD founders turn over the company to their sons.

1949 Wesley J. “Jack” Howe joins BD and becomes integral to developing sterility control procedures and refining the process for manufacturing disposable syringes and needles.

1949 BD opens its first manufacturing site outside of New Jersey in Columbus, Nebraska.

1949 BD launched the first Vacutainer® blood collection tube.

1921 Andrew W. “Doc” Fleischer, developer of the mercurial sphygmomanometer, merged his company with BD. Doc Fleischer would go on to develop the modern stethoscope.

1924 BD launched the first insulin injection device.

1925 BD acquired the Yale™ Luer-Lok™ — the first simple, secure method for attaching and removing a needle from a syringe.

1897 BD is founded.

1898 BD acquired its first patent for an all-glass syringe.

1906 BD opened the first syringe and needle factory in the United States.

1913 BD merged with Oscar O.R. Schwidetzky’s surgical import company, bringing his Asepto™ bulb syringe along with helping to develop the American-made ACE® bandage.

Honors and Recognition

Environment,

Social and Governance

2021 Disability Equality Index

Environment,

Social and Governance

2021 Best Place to Work for LGBTQ Equality

Environment,

social and governance

2021 Bloomberg Gender Equality Index

Environment,

Social and Governance

Fortune Change the World 2020

Technology and Innovation

2021 Clarivate Top 100 Global Innovator

Environment,

Social and Governance

2021 DiversityInc Noteworthy Company

BD Interventional

The BD Interventional segment focuses on developing innovative surgical, endovascular, urological and critical care interventions that not only meet clinical needs but also deliver value to health systems and improve patients’ lives. Our customers include hospitals and clinics; physicians; ambulatory surgery centers; nurses; and consumers.

BUSINESS UNITS

Peripheral Intervention
Surgery
Urology and Critical Care

BD Medical

The BD Medical segment focuses on providing innovative solutions to reduce the spread of infection, advance drug delivery, improve surgical procedures and provide effective and safe medication management. Our customers include hospitals and clinics; physicians; governmental and public health agencies; healthcare workers; retail pharmacies; pharmaceutical and biotech companies.

BUSINESS UNITS

Medication Delivery Solutions
Medication Management Solutions
Pharmaceutical Systems

BD Life Sciences

The BD Life Sciences segment delivers innovative solutions from discovery to diagnosis, continually advancing science and clinical outcomes across infectious disease and cancer. Offerings include preanalytical solutions for sample management; immunology research solutions, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics solutions; and differentiated reagents and assays.

BUSINESS UNITS

Biosciences
Integrated Diagnostic Solutions

BD is committed to creating an environment in which all associates feel comfortable raising concerns, seeking guidance, or asking questions without fear of retaliation or discipline.

Except as prohibited by applicable law, BD associates are obligated to report any suspected violations of laws, industry codes, the BD Code of Conduct, or BD policies in accordance with the BD Global Speaking Up Policy.

Anyone can seek guidance or report ethics concerns in a number of ways, including the BD Ethics Helpline or via email. The Helpline is independently operated and available anywhere in the world 24 hours a day, 7 days a week. The Helpline can be reached by telephone or online. The Helpline provides translation services as needed, and reports can be made anonymously where permitted by law. BD associates can also report violations to their supervisor, management, Human Resources, the Law Group or directly to Ethics & Compliance.

BD takes all reports of violations of laws, BD policies, and ethical standards seriously and will promptly, fairly, and thoroughly investigate all such reports. BD does not tolerate any form of retaliation against any person who in good faith reports an actual or suspected violation or cooperates in BD investigations.

The BD Code of Conduct sets the foundation for how we behave at BD. Our value “We do what is right” is the cornerstone of our Code. To do what is right, we follow the laws, rules, and company policies that apply to us. We also follow the highest ethical standards, even when there’s no specific law or policy. Our Code provides guidance and resources to help us follow through on these ethical standards and protect our reputation.

Everyone at BD—from directors to officers and associates—must follow our Code. It applies equally to everyone, no matter their position or level. BD associates receive information and training about the Code, and other policies in several ways, including periodic communications and trainings. Associates can access detailed information on our expectations through our intranet and on our ethics and compliance mobile app.

Select a language

English

English Arabic Bosnian Chinese Croatian Czech Danish Dutch - Belgium Dutch - Netherlands Finnish French - CA French - FR German Greek Hebrew Hindi Hungarian Italian Japanese Korean Norwegian Polish Portuguese Russian Serbian Spanish - EU Spanish - LA Swedish Thai Turkish Ukrainian Urdu Vietnamese

We work in the most dynamic and consequential industry in the world. The products we make today are a vital part of the global healthcare system,
and we have the capability to change even more lives in the future as we work together to fulfill our Purpose of advancing the world of health™.

Our Purpose comes with enormous responsibility, and how we deliver on this promise is just as important as what we ultimately accomplish. The answer can be found in The BD WAY the values, mindset, and leadership commitments that surround our Purpose and in one value in particular: "We do what is right." This is the foundation of our Code of Conduct, which guides every decision we make, every action we take, and every interaction we have with our customers, our business partners, our communities, and each other. This includes speaking up when we have concerns and seeking help when we have questions.

Our Code of Conduct provides direction on how we must behave in any scenario, and it applies to all of us, equally. Nothing is more essential to our success than doing the right thing; by familiarizing yourself with the Code of Conduct, you'll be taking an important step in helping us fulfill our Purpose and potential the right way-The BD WAY.

—

Tom Polen, Chairman, CEO and President

ENGLISH SUBTITLES

ENGLISH SUBTITLES ARABIC SUBTITLES BOSNIAN SUBTITLES CHINESE SUBTITLES DUTCH SUBTITLES FRENCH (FRANCE) SUBTITLES FRENCH CANADIAN GERMAN SUBTITLES GREEK SUBTITLES HUNGARIAN SUBTITLES HEBREW SUBTITLES ITALIAN SUBTITLES JAPANESE SUBTITLES KOREAN SUBTITLES POLISH SUBTITLES PORTUGUESE SUBTITLES RUSSIAN SUBTITLES SPANISH (SPAIN) SPANISH (LATIN AMERICAN) SUBTITLES TURKISH SUBTITLES

At BD, we are committed to a strong ethics and compliance culture. We do not tolerate actions or behaviors that are inconsistent with our values or violate the BD Code of Conduct or applicable laws and regulations. All BD associates are responsible for reinforcing our ethics and compliance culture and sustaining our reputation as a company dedicated to quality and integrity. We encourage and expect everyone at BD to speak up by asking questions, raising concerns, seeking guidance, and reporting actual or suspected violations of laws, our Code of Conduct, our policies, or our high ethical standards. This requirement extends to all associates, vendors, and other third parties working on our behalf.

The BD Values further strengthen our culture of ethics and compliance and guide how we hold ourselves accountable to our shareholders and stakeholders.

We do what is right.
We thrive on innovation and demand quality.
We are all accountable.
We learn and improve every day.
We help each other be great.

Under the oversight of the Audit Committee of the Board of Directors, BD’s global Ethics & Compliance function seeks to ensure that BD has a comprehensive compliance program that is designed to prevent and detect wrongdoing and continuously encourages lawful and ethical conduct. BD’s Senior Vice President & Chief Ethics and Compliance Officer leads the global Ethics & Compliance function and along with the BD Ethics & Compliance Committee, which is comprised of members of BD’s executive leadership team, oversees these activities to ensure effective operation and enforcement of BD’s global Ethics & Compliance program. The program is integrated into our global business operations. We evaluate the effectiveness of our program and adapt it periodically to ensure it is appropriately tailored to address the risks inherent in our global business.

Acting with integrity is critical to ensuring our success and protecting our reputation as we strive to advance the world of health. Associates and external business partners must conduct their activities in full compliance with all applicable antibribery and anticorruption laws, including local laws and industry codes in the countries where BD operates, as well as laws with cross‐border implications such as the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act.

Strong, long-term relationships with healthcare professionals (HCPs), healthcare organizations (HCOs), and government officials (GOs) help us better understand our customers and their patients’ needs. Through collaboration, we continue to develop high-quality products and teach people about their safe and effective use. These relationships must be based on the highest ethical standards. We must ensure that such interactions do not involve bribery, corruption, or other improper behavior. For these reasons, we do not offer, promise, provide, authorize, or accept improper payments, and we record all payments accurately. It’s critical that we avoid even the appearance of trying to bribe someone.

The Ethics & Compliance function provides resources to regional and local country management to enhance their anticorruption and compliance business practices. This includes incorporating compliance requirements into existing business practices and advising local management on anticorruption compliance-related issues.

BD holds the value that “We do what is right” and is fully committed to upholding the highest ethical standards set forth by all government regulatory bodies and all industry codes surrounding conduct engaging HCPs and HCOs.

We comply with all applicable laws and regulations that govern the interactions between medical technology companies and healthcare professionals, healthcare organizations and government officials in the many countries in which we do business.

In addition to our Code, BD has a set of global policies and standards, including our Global Standards for Interactions with Healthcare Providers, Health Care Organizations and Government Officials, which are designed to provide associates clear guidance on how to do what is right in the context of their work for BD.

BD has also adhered to various industry codes, including those of AdvaMed, APACMed, MedTech Europe, Mecomed, and ABIMED.

true